MD vs THC vs NKTR vs HCA vs CYH

For growth investors, HCA Healthcare, Inc.

(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Tenet Healthcare Corporation (THC) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Community Health Systems, Inc.

(CYH) is the cheapest at 0. 8x versus HCA Healthcare, Inc. at 15. 1x. On forward P/E, Pediatrix Medical Group, Inc. is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.

4%, compared to -81. 0% for Community Health Systems, Inc. (CYH). Over 10 years, the gap is even starker: THC returned +523. 4% versus CYH's -80. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HCA Healthcare, Inc.

(HCA) is the lower-risk stock at 0. 29β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 546% more volatile than HCA relative to the S&P 500. On balance sheet safety, Pediatrix Medical Group, Inc. (MD) carries a lower debt/equity ratio of 76% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HCA Healthcare, Inc.

(HCA) is pulling ahead at 7. 1% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, HCA leads at 7. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HCA Healthcare, Inc.

(HCA) is the more profitable company, earning 9. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pediatrix Medical Group, Inc. (MD) trades at 10. 3x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, HCA (0.

7% yield) pays a dividend. MD, THC, NKTR, CYH do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, HCA Healthcare, Inc.

(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +450. 5%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MD is a small-cap deep-value stock; THC is a mid-cap deep-value stock; NKTR is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock; CYH is a small-cap deep-value stock. HCA pays a dividend while MD, THC, NKTR, CYH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.